BioSpace News Archive

Mablink Bioscience, a biotechnology company dedicated to advancing cancer therapy with next-generation antibody-drug conjugates, announced the appointment of Dr. Pejvack Motlagh, M.D., as Chief Medical Officer.

bit.bio, a synthetic biology company focused on human cells, has achieved a milestone in the manufacture of human cells.

Biolog, Inc., a leading provider of microbial polyphasic analysis, announced the launch of the Odin™ system, an all-in-one cellular phenotyping and microbial identification platform.

Zentalis® Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 11,032,656 shares of its common stock at an offering price of $22.66 per share, for total gross proceeds of approximately $250.0 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

NS Pharma, Inc. announced the U.S. Food & Drug Administration has agreed to the planned Phase I/II study of NS-050/NCNP-03, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 50 skipping therapy.

Breast Cancer Canada announced a new research grant in collaboration with AstraZeneca Canada, a global, science-led biopharmaceutical company and Illumina, a global leader in DNA sequencing and array-based technologies.

DEXIS IOS Solutions is pleased to announce the expansion of its portfolio and ecosystem through new digital end-to-end workflows.

Jubilant Therapeutics Inc. announced the appointment of Nadir Patel as an independent director on the Company’s Board of Directors.

Nikon Instruments Inc. is pleased to announce the development and launch of the “ECLIPSE Ui”, an integrated microscope-based viewing system designed for both in-person clinical and remote pathological observation.

First Wave BioPharma, Inc. announced that it will attend the Cystic Fibrosis Research Institute’s 36th National Cystic Fibrosis Education Conference being held July 28-30, 2023, at the Grand Bay Hotel San Francisco in Redwood City, California.